Tazorac

Product manufactured by Allergan, Inc.

Application Nr Approved Date Route Status External Links
NDA020600 None Cutaneous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Tazorac ® Gel, 0.05% And 0.1% Is A Retinoid Indicated For The Topical Treatment Of Plaque Psoriasis Of Up To 20% Body Surface Area Involvement. ( 1.1 ) Tazorac Gel, 0.1% Is Indicated For The Topical Treatment Of Mild To Moderate Facial Acne Vulgaris. ( 1.2 ) Limitations Of Use The Safety Of Tazorac Gel Use On More Than 20% Body Surface Area Has Not Been Established. ( 1.3 ) 1.1 Plaque Psoriasis Tazorac® (Tazarotene) Gel, 0.05% And 0.1% Are Indicated For The Topical Treatment Of Patients With Plaque Psoriasis Of Up To 20% Body Surface Area Involvement. 1.2 Acne Vulgaris Tazorac (Tazarotene) Gel, 0.1% Is Also Indicated For The Topical Treatment Of Patients With Facial Acne Vulgaris Of Mild To Moderate Severity. The Efficacy Of Tazorac Gel In The Treatment Of Acne Previously Treated With Other Retinoids Or Resistant To Oral Antibiotics Has Not Been Established. 1.3 Limitations Of Use The Safety Of Tazorac Gel Use On More Than 20% Body Surface Area Has Not Been Established In Psoriasis Or Acne [See Warnings And Precautions ( 5.1 ) And Use In Specific Populations ( 8.1 )].

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Tazarotene TAZAROTENE ZINC1542199

Comments